Future Directions. Lung Aging, Inflammation, and Human Immunodeficiency Virus.

Clinics in Chest Medicine

Volumn 34, Issue 2, 2013, Pages 325-331

  Fitzpatrick, Meghan ^a   Crothers, Kristina ^b   Morris, Alison ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chronic obstructive pulmonary disease; Human immunodeficiency virus; Immune activation; Immune senescence; Inflammation; Pulmonary hypertension

Indexed keywords

ANTIRETROVIRUS AGENT;

AGING; CARDIOPULMONARY INSUFFICIENCY; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SENESCENCE; IMMUNOSTIMULATION; INFLAMMATION; LUNG DISEASE; LUNG INSUFFICIENCY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

AGE OF ONSET; AGING; HIV; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84878151219     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.01.010     Document Type: Review

References (63)

1. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Hall H.I., Song R., Rhodes P., et al. Estimation of HIV incidence in the United States. JAMA 2008, 300:520-529.
3. Justice A.C. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010, 7:69-76.
4. Effros R.B., Fletcher C.V., Gebo K., et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008, 47:542-553.
5. Clifford D.B. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 2008, 16:94-98.
6. Wand H., Calmy A., Carey D.L., et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21:2445-2453.
7. Bozzette S.A., Ake C.F., Tam H.K., et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710.
8. Deeks S.G. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011, 62:141-155.
9. Crothers K. Chronic obstructive pulmonary disease in patients who have HIV infection. Clin Chest Med 2007, 28:575-587. vi.
10. Crothers K., Butt A.A., Gibert C.L., et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006, 130:1326-1333.
11. Crothers K., Huang L., Goulet J.L., et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011, 183:388-395.
12. Cui Q., Carruthers S., McIvor A., et al. Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. AIDS Res Ther 2010, 7:6.
13. Diaz P.T., King M.A., Pacht E.R., et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000, 132:369-372.
14. George M.P., Kannass M., Huang L., et al. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS One 2009, 4:e6328.
15. Gingo M.R., George M.P., Kessinger C.J., et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med 2010, 182:790-796.
16. Gingo M.R., Morris A. Pathogenesis of HIV and the lung. Curr HIV/AIDS Rep 2012, 10:42-50.
17. Hirani A., Cavallazzi R., Vasu T., et al. Prevalence of obstructive lung disease in HIV population: a cross sectional study. Respir Med 2011, 105:1655-1661.
18. Morris A., Gingo M.R., George M.P., et al. Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era. AIDS 2012, 26:731-740.
19. Petrache I., Diab K., Knox K.S., et al. HIV-associated pulmonary emphysema: a review of the literature and inquiry into its mechanism. Thorax 2008, 63:463-469.
20. Sitbon O., Lascoux-Combe C., Delfraissy J.F., et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008, 177:108-113.
21. Mondy K.E., Gottdiener J., Overton E.T., et al. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin Infect Dis 2011, 52:378-386.
22. Aoshiba K., Nagai A. Senescence hypothesis for the pathogenetic mechanism of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009, 6:596-601.
23. Ito K., Barnes P.J. COPD as a disease of accelerated lung aging. Chest 2009, 135:173-180.
24. Karrasch S., Holz O., Jorres R.A. Aging and induced senescence as factors in the pathogenesis of lung emphysema. Respir Med 2008, 102:1215-1230.
25. Lambers C., Hacker S., Posch M., et al. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2009, 155:466-475.
26. MacNee W. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem Soc Trans 2009, 37:819-823.
27. Tsuji T., Aoshiba K., Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 2006, 174:886-893.
28. Gadgil A., Duncan S.R. Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008, 3:531-541.
29. Lam C.S., Borlaug B.A., Kane G.C., et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009, 119:2663-2670.
30. Noureddine H., Gary-Bobo G., Alifano M., et al. Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease. Circ Res 2011, 109:543-553.
31. Karrer U., Sierro S., Wagner M., et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol 2003, 170:2022-2029.
32. Hunt P.W., Martin J.N., Sinclair E., et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011, 203:1474-1483.
33. Kovacs A., Karim R., Mack W.J., et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010, 201:823-834.
34. Sajadi M.M., Pulijala R., Redfield R.R., et al. Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors. AIDS 2012, 26:1879-1884.
35. Effros R.B. Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. Dev Comp Immunol 1997, 21:471-478.
36. Yi J.S., Cox M.A., Zajac A.J. T-cell exhaustion: characteristics, causes and conversion. Immunology 2010, 129:474-481.
37. Vallejo A.N., Weyand C.M., Goronzy J.J. T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection. Trends Mol Med 2004, 10:119-124.
38. Sansoni P., Vescovini R., Fagnoni F., et al. The immune system in extreme longevity. Exp Gerontol 2008, 43:61-65.
39. Cao W., Jamieson B.D., Hultin L.E., et al. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 2009, 50:137-147.
40. Desai S., Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010, 7:4-10.
41. Appay V., Papagno L., Spina C.A., et al. Dynamics of T cell responses in HIV infection. J Immunol 2002, 168:3660-3666.
42. Valdez H., Connick E., Smith K.Y., et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002, 16:1859-1866.
43. Hunt P.W., Martin J.N., Sinclair E., et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003, 187:1534-1543.
44. Kaplan R.C., Sinclair E., Landay A.L., et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011, 203:452-463.
45. Xu JQ, Kochanek K, Tejada-Vera B. Deaths: preliminary data for 2007. National Vital Statistics Reports. National Center for Health Statistics. 2009;58.
46. Mannino D.M., Gagnon R.C., Petty T.L., et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000, 160:1683-1689.
47. Niaura R., Shadel W.G., Morrow K., et al. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis 2000, 31:808-812.
48. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med 2000, 343:269-280.
49. Casanova C., de Torres J.P., Aguirre-Jaime A., et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med 2011, 184:1015-1021.
50. Agusti A., Edwards L.D., Rennard S.I., et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012, 7:e37483.
51. Hodge G., Nairn J., Holmes M., et al. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects. Clin Exp Immunol 2007, 150:22-29.
52. Arimura K., Aoshiba K., Tsuji T., et al. Chronic low-grade systemic inflammation causes DNA damage in the lungs of mice. Lung 2012, 190(6):613-620.
53. Tsuji T., Aoshiba K., Nagai A. Alveolar cell senescence exacerbates pulmonary inflammation in patients with chronic obstructive pulmonary disease. Respiration 2010, 80:59-70.
54. Houben J.M., Mercken E.M., Ketelslegers H.B., et al. Telomere shortening in chronic obstructive pulmonary disease. Respir Med 2009, 103:230-236.
55. Savale L., Chaouat A., Bastuji-Garin S., et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179:566-571.
56. Speich R., Jenni R., Opravil M., et al. Primary pulmonary hypertension in HIV infection. Chest 1991, 100:1268-1271.
57. Hsue P.Y., Deeks S.G., Farah H.H., et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 2008, 22:825-833.
58. George M.P., Champion H.C., Simon M., et al. Physiologic changes in a non-human primate model of HIV-associated pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2012, [Epub ahead of print].
59. Price L.C., Wort S.J., Perros F., et al. Inflammation in pulmonary arterial hypertension. Chest 2012, 141:210-221.
60. Cicalini S., Almodovar S., Grilli E., et al. Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. Clin Microbiol Infect 2011, 17:25-33.
61. Perros F., Dorfmuller P., Montani D., et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 185:311-321.
62. El Chami H., Hassoun P.M. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012, 55:218-228.
63. Plaeger S.F., Collins B.S., Musib R., et al. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses 2012, 28:469-477.